Table A1.
Baseline characteristics of all patients with GC-induced diabetes vs. patients with normoglycemia.
| No Pre-Existing Diabetes (n = 1913) | GC-Induced Diabetes (n = 399) | Normoglycemia (n = 1514) |
p-Value | |
|---|---|---|---|---|
| Male sex, n (%) | 915 (47.8%) | 188 (47%) | 727 (48%) | 0.78 |
| Age, y, mean (SD) | 66 (±15.6) | 65.92 (±15.71) | 65.52 (±16.01) | 0.65 |
| Body mass index kg/m2 (IQR) | 24.6 (21.6–28) | 25.3 (22–29) | 24.38 (21–28) | <0.001 |
| Mean glucocorticoid (GC) dose 1, mg/kg/day | 0.89 (±2.4) | 1.79 (±4.1) | 0.65 (±1.6) | <0.001 |
| Duration of GC administration (in days) | 4.61 ± 2.2 | 5.33 (±2.1) | 4.42 (±2.2) | <0.001 |
| Length of stay | 8.0 (5.0–13.0) | 9.0 (5.0–15.0) | 8.0 (5.0–13.0) | <0.001 |
| Charlson Comorbidity Index | 2.0 (1.0–4.0) | 2.00 (1.0–3.0) | 2.0 (1.0–4.0) | 0.38 |
| Glucose on admission, | 6.50 (5.65–7.7) mmol/L/ 117 (102–139) mg/dL |
7.10 (5.9–8.8) mmol/L/ 128 (106–159) mg/dL |
6.33 (5.6–7.4) mmol/L/ 114 (101–133) mg/dL |
<0.001 |
| Mean glucose differences from peaks to nadirs (MAGE) | 3.06 (±1.65) | 4.12 (±1.87) | 2.37 (±1.0) | <0.001 |
| Glucose (coefficient of variation) 2 | 0.23 (±0.09) | 0.27 (± 0.09) | 0.2 (±0.07) | <0.001 |
| Indication for GC administration | 0.010 | |||
| Autoimmune-inflammatory | 631 (33%) | 156 (39.1%) | 475 (31.4%) | |
| Oncology | 577 (30.2%) | 99 (24.8%) | 478 (31.6%) | |
| Pneumology/Infectiology | 617 (32.3%) | 123 (30.8%) | 494 (32.6%) | |
| Endocrinology/others | 88 (4.6%) | 21 (5.3%) | 67 (4.4%) |
Data is shown as n (%) or mean/median (standard deviation or interquartile range) per group. 1 mean GC dose is given as normalized GC dose in mg per prednisolone equivalent per kg per day. 2 CV = SD/mean ∗ 100%. GC: glucocorticoid.